<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2009-02-12" updated="2020-01-02">
  <drugbank-id primary="true">DB06692</drugbank-id>
  <name>Aprotinin</name>
  <description>Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use.</description>
  <cas-number>9087-70-1</cas-number>
  <unii>04XPW8C0FL</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A6968</ref-id>
        <pubmed-id>15277296</pubmed-id>
        <citation>Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Marion Steinbuch, Jacques Chabbat, Olivier Taby, "Process for preparation of activated protein C by immobilized aprotinin chromatography." U.S. Patent US5198534, issued February, 1985.</synthesis-reference>
  <indication>For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.</indication>
  <pharmacodynamics>Aprotinin is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Aprotinin, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of aprotinin use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.</pharmacodynamics>
  <mechanism-of-action>Aprotinin inhibits serine proteases including trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/mL, and kallikrein at 300,000 IU/mL. The inhibition of kallikrein inhibits formation of factor XIIa. This inhibits the intrinsic pathway of coagulation and fibrinolysis. Inhibition of plasmin also slows fibrinolysis.</mechanism-of-action>
  <toxicity/>
  <metabolism>Aprotinin is slowly degraded by lysosomal enzymes.</metabolism>
  <absorption>100% (IV)</absorption>
  <half-life>Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.</half-life>
  <protein-binding/>
  <route-of-elimination>Following a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours.&#13;
After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug.&#13;
After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Aprotinin (bovine)</synonym>
    <synonym language="english" coder="">Aprotinin Biosynthetic</synonym>
    <synonym language="english" coder="">Aprotinin Bovine</synonym>
    <synonym language="english" coder="">Aprotinin Concentrated Solution</synonym>
    <synonym language="spanish" coder="">Aprotinina</synonym>
    <synonym language="english" coder="">Bovine Aprotinin</synonym>
    <synonym language="english" coder="">Bovine Pancreatic Trypsin Inhibitor</synonym>
    <synonym language="english" coder="">BPTI</synonym>
    <synonym language="english" coder="">Fibrinolysis Inhibitor</synonym>
    <synonym language="english" coder="">Trypsin Inhibitor, Pancreatic Basic</synonym>
  </synonyms>
  <products>
    <product>
      <name>Artiss</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326167</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326175</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Tisseel</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02326132</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trasylol</name>
      <labeller>Nordic Group Bv</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02186845</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>10000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trasylol</name>
      <labeller>Bayer Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0026-8197</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-09</started-marketing-on>
      <ended-marketing-on>2018-08-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>2000000</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trasylol</name>
      <labeller>Bayer Pharmaceuticals Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0026-8196</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-01-09</started-marketing-on>
      <ended-marketing-on>2018-08-02</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>1000000</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trasylol Inj 10000 Kiu/ml</name>
      <labeller>Miles Canada Inc.   Pharmaceutical Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00513954</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1998-09-25</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Trasylol</name>
      <ingredients>Aprotinin</ingredients>
    </mixture>
    <mixture>
      <name>Trasylol</name>
      <ingredients>Aprotinin</ingredients>
    </mixture>
    <mixture>
      <name>Trasylol Inj 10000 Kiu/ml</name>
      <ingredients>Aprotinin</ingredients>
    </mixture>
    <mixture>
      <name>Trasylol</name>
      <ingredients>Aprotinin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Artiss</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
    <mixture>
      <name>Tisseel</name>
      <ingredients>Aprotinin + Calcium chloride + Fibrinogen human + Human Thrombin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Baxter International Inc.</name>
      <url>http://www.baxter.com</url>
    </packager>
    <packager>
      <name>Bayer Healthcare</name>
      <url>http://www.bayerhealthcare.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antifibrinolytic Agents</category>
      <mesh-id>D000933</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cholinesterase Inhibitors</category>
      <mesh-id>D002800</mesh-id>
    </category>
    <category>
      <category>Coagulants</category>
      <mesh-id>D003029</mesh-id>
    </category>
    <category>
      <category>Decreased Fibrinolysis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Proteinase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Serine Protease Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>Trypsin Inhibitors</category>
      <mesh-id>D014361</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>10000 unit</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>1000000</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>2000000</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02AB01">
      <level code="B02AB">Proteinase inhibitors</level>
      <level code="B02A">ANTIFIBRINOLYTICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:28.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06692.pdf?1265922812</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06692.pdf?1265922748</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The therapeutic efficacy of Abciximab can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The therapeutic efficacy of Anagrelide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Dicoumarol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The therapeutic efficacy of Argatroban can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The therapeutic efficacy of Iloprost can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The therapeutic efficacy of Defibrotide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The therapeutic efficacy of Ancrod can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The therapeutic efficacy of Fibrinolysin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The therapeutic efficacy of Sulodexide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The therapeutic efficacy of Astaxanthin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The therapeutic efficacy of Amediplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The therapeutic efficacy of Danaparoid can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The therapeutic efficacy of Tinzaparin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The therapeutic efficacy of Edoxaban can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The therapeutic efficacy of Protein C can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The therapeutic efficacy of Monteplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The therapeutic efficacy of Brinase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The therapeutic efficacy of Saruplase can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Omapatrilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>Aprotinin may decrease the antihypertensive activities of Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>Aprotinin may decrease the antihypertensive activities of Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Trandolaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Moexiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>Aprotinin may decrease the antihypertensive activities of Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>Aprotinin may decrease the antihypertensive activities of Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Succinylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Ephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05875</drugbank-id>
      <name>Sar9, Met (O2)11-Substance P</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04250</drugbank-id>
      <name>Butyrylthiocholine</name>
      <description>Aprotinin may increase the neuromuscular blocking activities of Butyrylthiocholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00058</drugbank-id>
      <name>Alpha-1-proteinase inhibitor</name>
      <description>Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00170</drugbank-id>
      <name>Menadione</name>
      <description>Menadione may increase the thrombogenic activities of Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00302</drugbank-id>
      <name>Tranexamic acid</name>
      <description>Tranexamic acid may increase the thrombogenic activities of Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00513</drugbank-id>
      <name>Aminocaproic acid</name>
      <description>Aminocaproic acid may increase the thrombogenic activities of Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11091</drugbank-id>
      <name>Hydrogen peroxide</name>
      <description>Aprotinin may increase the thrombogenic activities of Hydrogen peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13244</drugbank-id>
      <name>Aminomethylbenzoic acid</name>
      <description>Aprotinin may increase the thrombogenic activities of Aminomethylbenzoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13729</drugbank-id>
      <name>Camostat</name>
      <description>Aprotinin may increase the thrombogenic activities of Camostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09222</drugbank-id>
      <name>Fibrinogen human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of Thrombosis can be increased when Tretinoin is combined with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Tramadol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The therapeutic efficacy of Trospium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The therapeutic efficacy of Butabarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The therapeutic efficacy of Benzatropine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Disopyramide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The therapeutic efficacy of Talbutal can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The therapeutic efficacy of Ipratropium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Methadone can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Olanzapine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Metixene can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The therapeutic efficacy of Terfenadine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The therapeutic efficacy of Buclizine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Clozapine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The therapeutic efficacy of Doxylamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Procyclidine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Profenamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The therapeutic efficacy of Promazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The therapeutic efficacy of Imipramine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The therapeutic efficacy of Darifenacin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The therapeutic efficacy of Amoxapine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The therapeutic efficacy of Atropine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The therapeutic efficacy of Nicardipine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The therapeutic efficacy of Paroxetine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The therapeutic efficacy of Procaine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The therapeutic efficacy of Scopolamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The therapeutic efficacy of Isoflurane can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The therapeutic efficacy of Clidinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>The therapeutic efficacy of Propiomazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>The therapeutic efficacy of Propantheline can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Primidone can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Biperiden can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The therapeutic efficacy of Flupentixol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The therapeutic efficacy of Cocaine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The therapeutic efficacy of Quinidine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Amantadine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The therapeutic efficacy of Maprotiline can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>The therapeutic efficacy of Methantheline can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>The therapeutic efficacy of Cycrimine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The therapeutic efficacy of Desloratadine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The therapeutic efficacy of Tolterodine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The therapeutic efficacy of Promethazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The therapeutic efficacy of Doxepin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>The therapeutic efficacy of Flavoxate can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The therapeutic efficacy of Desipramine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The therapeutic efficacy of Chloroprocaine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The therapeutic efficacy of Escitalopram can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Quetiapine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>The therapeutic efficacy of Diphenidol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Fenoterol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The therapeutic efficacy of Butobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The therapeutic efficacy of Heptabarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The therapeutic efficacy of Tiotropium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The therapeutic efficacy of Barbituric acid derivative can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The therapeutic efficacy of Solifenacin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>The therapeutic efficacy of Isopropamide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The therapeutic efficacy of Gantacurium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>The therapeutic efficacy of Pizotifen can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>The therapeutic efficacy of Dimetindene can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The therapeutic efficacy of Agmatine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The therapeutic efficacy of Aclidinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Dexetimide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The therapeutic efficacy of Benactyzine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The therapeutic efficacy of Trimebutine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The therapeutic efficacy of Dosulepin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>The therapeutic efficacy of Imidafenacin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The therapeutic efficacy of Revefenacin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>The therapeutic efficacy of Oxitropium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>The therapeutic efficacy of Propiverine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Batefenterol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>The therapeutic efficacy of Mebeverine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Tropatepine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>The therapeutic efficacy of Prifinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>The therapeutic efficacy of Piperidolate can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>The therapeutic efficacy of Benzilone can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>The therapeutic efficacy of Difemerine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Mazaticol can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The therapeutic efficacy of Otilonium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The therapeutic efficacy of Emepronium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>The therapeutic efficacy of Poldine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>The therapeutic efficacy of Bevonium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>The therapeutic efficacy of Rociverine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Bornaprine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Etanautine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>The therapeutic efficacy of Tiemonium iodide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>The therapeutic efficacy of Penthienate can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>The therapeutic efficacy of Diphemanil can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>The therapeutic efficacy of Camylofin can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>The therapeutic efficacy of Fenpiverinium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>The therapeutic efficacy of Emetonium iodide can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>The therapeutic efficacy of Timepidium can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Aprotinin may increase the bradycardic activities of Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>Aprotinin may increase the bradycardic activities of Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>Aprotinin may increase the bradycardic activities of Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>Aprotinin may increase the bradycardic activities of Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>Aprotinin may increase the bradycardic activities of Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>Aprotinin may increase the bradycardic activities of Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>Aprotinin may increase the bradycardic activities of Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Aprotinin may increase the bradycardic activities of Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>Aprotinin may increase the bradycardic activities of Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>Aprotinin may increase the bradycardic activities of Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Aprotinin may increase the bradycardic activities of Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>Aprotinin may increase the bradycardic activities of Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>Aprotinin may increase the bradycardic activities of Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>Aprotinin may increase the bradycardic activities of Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>Aprotinin may increase the bradycardic activities of Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>Aprotinin may increase the bradycardic activities of Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>Aprotinin may increase the bradycardic activities of Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Aprotinin may increase the bradycardic activities of Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>Aprotinin may increase the bradycardic activities of Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>Aprotinin may increase the bradycardic activities of Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>Aprotinin may increase the bradycardic activities of Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>Aprotinin may increase the bradycardic activities of Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Aprotinin may increase the bradycardic activities of Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Aprotinin may increase the bradycardic activities of Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>Aprotinin may increase the bradycardic activities of Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>Aprotinin may increase the bradycardic activities of Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Aprotinin may increase the bradycardic activities of Befunolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Aprotinin may increase the bradycardic activities of Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>Aprotinin may increase the bradycardic activities of Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>Aprotinin may increase the bradycardic activities of Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Aprotinin may increase the bradycardic activities of Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Aprotinin may increase the bradycardic activities of Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Aprotinin may increase the bradycardic activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>Aprotinin may increase the bradycardic activities of Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>Aprotinin may increase the bradycardic activities of Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Aprotinin may increase the bradycardic activities of Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>Aprotinin may increase the bradycardic activities of Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Aprotinin may increase the bradycardic activities of Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Cevimeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00411</drugbank-id>
      <name>Carbamoylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Carbamoylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01019</drugbank-id>
      <name>Bethanechol</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Bethanechol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Varenicline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03128</drugbank-id>
      <name>Acetylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Acetylcholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04365</drugbank-id>
      <name>Arecoline</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Arecoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05137</drugbank-id>
      <name>Lobeline</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Lobeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05152</drugbank-id>
      <name>NGX267</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with NGX267.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with GTS-21.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06709</drugbank-id>
      <name>Methacholine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Methacholine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07720</drugbank-id>
      <name>Epibatidine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Epibatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15357</drugbank-id>
      <name>Xanomeline</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Xanomeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Tixocortol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluocortin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluperolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Formocortal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluclorolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Hydrocortisone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Loteprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Methylprednisolone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Aprotinin can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Metocurine iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Cisatracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Rocuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Atracurium besylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Doxacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Mivacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>Aprotinin may decrease the neuromuscular blocking activities of Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00025</drugbank-id>
      <name>Antihemophilic factor, human recombinant</name>
      <description>Aprotinin may increase the thrombogenic activities of Antihemophilic factor, human recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00036</drugbank-id>
      <name>Coagulation factor VIIa Recombinant Human</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00100</drugbank-id>
      <name>Coagulation Factor IX (Recombinant)</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation Factor IX (Recombinant).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium Chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01783</drugbank-id>
      <name>Pantothenic acid</name>
      <description>Aprotinin may increase the thrombogenic activities of Pantothenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01942</drugbank-id>
      <name>Formic acid</name>
      <description>Aprotinin may increase the thrombogenic activities of Formic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02261</drugbank-id>
      <name>Platelet Activating Factor</name>
      <description>Aprotinin may increase the thrombogenic activities of Platelet Activating Factor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09109</drugbank-id>
      <name>Turoctocog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Turoctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09310</drugbank-id>
      <name>Catridecacog</name>
      <description>Aprotinin may increase the thrombogenic activities of Catridecacog.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>Aprotinin may increase the thrombogenic activities of Antihemophilic Factor (Recombinant), PEGylated.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium Citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium gluconate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11168</drugbank-id>
      <name>Calcium threonate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium threonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11311</drugbank-id>
      <name>Prothrombin</name>
      <description>Aprotinin may increase the thrombogenic activities of Prothrombin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11330</drugbank-id>
      <name>Factor IX Complex (Human)</name>
      <description>Aprotinin may increase the thrombogenic activities of Factor IX Complex (Human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium Phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11606</drugbank-id>
      <name>Susoctocog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Susoctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Eftrenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11668</drugbank-id>
      <name>Rusalatide acetate</name>
      <description>Aprotinin may increase the thrombogenic activities of Rusalatide acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12409</drugbank-id>
      <name>Vatreptacog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Vatreptacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12909</drugbank-id>
      <name>Factor XIII (human)</name>
      <description>Aprotinin may increase the thrombogenic activities of Factor XIII (human).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13133</drugbank-id>
      <name>Von Willebrand Factor Human</name>
      <description>Aprotinin may increase the thrombogenic activities of Von Willebrand Factor Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13148</drugbank-id>
      <name>Coagulation factor X human</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation factor X human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13150</drugbank-id>
      <name>Coagulation factor VII human</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation factor VII human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13151</drugbank-id>
      <name>Anti-inhibitor coagulant complex</name>
      <description>Aprotinin may increase the thrombogenic activities of Anti-inhibitor coagulant complex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13152</drugbank-id>
      <name>Coagulation Factor IX Human</name>
      <description>Aprotinin may increase the thrombogenic activities of Coagulation Factor IX Human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13192</drugbank-id>
      <name>Antihemophilic factor human</name>
      <description>Aprotinin may increase the thrombogenic activities of Antihemophilic factor human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13197</drugbank-id>
      <name>Kallidinogenase</name>
      <description>Aprotinin may increase the thrombogenic activities of Kallidinogenase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13201</drugbank-id>
      <name>Trenonacog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Trenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Albutrepenonacog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>Aprotinin may increase the thrombogenic activities of Emicizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>Aprotinin may increase the thrombogenic activities of Nonacog beta pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13999</drugbank-id>
      <name>Moroctocog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Moroctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14473</drugbank-id>
      <name>Beroctocog alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Beroctocog alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14562</drugbank-id>
      <name>Andexanet alfa</name>
      <description>Aprotinin may increase the thrombogenic activities of Andexanet alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>Aprotinin may increase the thrombogenic activities of Calcium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>Aprotinin may increase the thrombogenic activities of Damoctocog alfa pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14738</drugbank-id>
      <name>Turoctocog alfa pegol</name>
      <description>Aprotinin may increase the thrombogenic activities of Turoctocog alfa pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of adverse effects can be increased when Aprotinin is combined with Amifampridine.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Aprotinin (bovine pancreatic trypsin inhibitor)
RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>&gt;100 C</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>6511.439</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C284H432N84O79S7</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11567</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20461</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910361</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02971</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448472</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000185</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Aprotinin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201619</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/trasylol-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/aprotinin.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000288</smpdb-id>
      <name>Aprotinin Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB01022</drugbank-id>
          <name>Phylloquinone</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
        <drug>
          <drugbank-id>DB06692</drugbank-id>
          <name>Aprotinin</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P00747</uniprot-id>
        <uniprot-id>P00748</uniprot-id>
        <uniprot-id>P02452</uniprot-id>
        <uniprot-id>P03952</uniprot-id>
        <uniprot-id>P03951</uniprot-id>
        <uniprot-id>P00740</uniprot-id>
        <uniprot-id>P00451</uniprot-id>
        <uniprot-id>P00734</uniprot-id>
        <uniprot-id>P12259</uniprot-id>
        <uniprot-id>P00742</uniprot-id>
        <uniprot-id>P02671</uniprot-id>
        <uniprot-id>P02675</uniprot-id>
        <uniprot-id>P02679</uniprot-id>
        <uniprot-id>P00488</uniprot-id>
        <uniprot-id>P05160</uniprot-id>
        <uniprot-id>P00750</uniprot-id>
        <uniprot-id>P08709</uniprot-id>
        <uniprot-id>P13726</uniprot-id>
        <uniprot-id>Q9BQB6</uniprot-id>
        <uniprot-id>P38435</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001739</id>
      <name>Trypsin-1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A6968</ref-id>
            <pubmed-id>15277296</pubmed-id>
            <citation>Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07477" source="Swiss-Prot">
        <name>Trypsin-1</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.</specific-function>
        <gene-name>PRSS1</gene-name>
        <locus>7q32-qter|7q34</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-15</signal-regions>
        <theoretical-pi>6.48</theoretical-pi>
        <molecular-weight>26557.88</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9475</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PRSS1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M22612</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>521216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P07477</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TRY1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.4</synonym>
          <synonym>Beta-trypsin</synonym>
          <synonym>Cationic trypsinogen</synonym>
          <synonym>Serine protease 1</synonym>
          <synonym>TRP1</synonym>
          <synonym>TRY1</synonym>
          <synonym>TRYP1</synonym>
          <synonym>Trypsin I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016543|Trypsin-1
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016544|Trypsin-1 (PRSS1)
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTATGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cobalamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0003531</id>
      <name>Chymotrypsinogen B</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A6968</ref-id>
            <pubmed-id>15277296</pubmed-id>
            <citation>Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P17538" source="Swiss-Prot">
        <name>Chymotrypsinogen B</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function/>
        <gene-name>CTRB1</gene-name>
        <locus>16q23-q24.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>7.17</theoretical-pi>
        <molecular-weight>27869.74</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2521</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CTRB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>BC005385</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P17538</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CTRB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.1</synonym>
          <synonym>CTRB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017133|Chymotrypsinogen B
MAFLWLLSCWALLGTTFGCGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFC
GGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNND
ITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPL
LSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCST
SSPGVYARVTKLIPWVQKILAAN</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cobalamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000211</id>
      <name>Plasminogen</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A6968</ref-id>
            <pubmed-id>15277296</pubmed-id>
            <citation>Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P00747" source="Swiss-Prot">
        <name>Plasminogen</name>
        <general-function>Serine-type peptidase activity</general-function>
        <specific-function>Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.</specific-function>
        <gene-name>PLG</gene-name>
        <locus>6q26</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>7.25</theoretical-pi>
        <molecular-weight>90568.415</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9071</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PLG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X05199</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>387026</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2394</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P00747</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PLMN_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016037|Plasminogen
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016038|Plasminogen (PLG)
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00051</identifier>
            <name>Kringle</name>
          </pfam>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
          <pfam>
            <identifier>PF00024</identifier>
            <name>PAN_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extrinsic component of external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>apolipoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein domain specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type peptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix disassembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell-cell adhesion mediated by cadherin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell-substrate adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tissue remodeling</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0001091</id>
      <name>Kallikrein-1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A6968</ref-id>
            <pubmed-id>15277296</pubmed-id>
            <citation>Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06870" source="Swiss-Prot">
        <name>Kallikrein-1</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.</specific-function>
        <gene-name>KLK1</gene-name>
        <locus>19q13.3</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>4.39</theoretical-pi>
        <molecular-weight>28889.425</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6357</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>KLK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M25629</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>186653</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2865</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06870</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>KLK1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.35</synonym>
          <synonym>Kidney/pancreas/salivary gland kallikrein</synonym>
          <synonym>Tissue kallikrein</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037122|Kallikrein-1
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWV
LTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHD
LMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKIL
PNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNK
PSVAVRVLSYVKWIEDTIAENS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010764|Kallikrein-1 (KLK1)
ATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCG
ATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCG
GCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTG
CTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTG
TTTGACGACGAAAACACAGCCCAGTTTGTTCATGTCAGTGAGAGCTTCCCACACCCTGGC
TTCAACATGAGCCTCCTGGAGAACCACACCCGCCAAGCAGACGAGGACTACAGCCACGAC
CTCATGCTGCTCCGCCTGACAGAGCCTGCTGATACCATCACAGATGCTGTGAAGGTCGTG
GAGTTGCCCACCGAGGAACCCGAAGTGGGGAGCACCTGTTTGGCTTCCGGCTGGGGCAGC
ATCGAACCAGAGAATTTCTCATTTCCAGATGATCTCCAGTGTGTGGACCTCAAAATCCTG
CCTAATGATGAGTGCAAAAAAGCCCACGTCCAGAAGGTGACAGACTTCATGCTGTGTGTC
GGACACCTGGAAGGTGGCAAAGACACCTGTGTGGGTGATTCAGGGGGCCCGCTGATGTGT
GATGGTGTGCTCCAAGGTGTCACATCATGGGGCTACGTCCCTTGTGGCACCCCCAATAAG
CCTTCTGTCGCCGTCAGAGTGCTGTCTTATGTGAAGTGGATCGAGGACACCATAGCGGAG
AACTCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>zymogen activation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002180</id>
      <name>Cholinesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks>
          <textbook>
            <ref-id>T343</ref-id>
            <isbn>0444537163</isbn>
            <citation>Jeffrey K. Aronson (2015). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (16th ed.). Elsevier.</citation>
          </textbook>
        </textbooks>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P06276" source="Swiss-Prot">
        <name>Cholinesterase</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.</specific-function>
        <gene-name>BCHE</gene-name>
        <locus>3q26.1-q26.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>7.47</theoretical-pi>
        <molecular-weight>68417.575</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:983</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>BCHE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32391</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1311630</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2471</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CHLE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.8</synonym>
          <synonym>Acylcholine acylhydrolase</synonym>
          <synonym>Butyrylcholine esterase</synonym>
          <synonym>CHE1</synonym>
          <synonym>Choline esterase II</synonym>
          <synonym>Pseudocholinesterase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016706|Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016707|Cholinesterase (BCHE)
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
          <pfam>
            <identifier>PF08674</identifier>
            <name>AChE_tetra</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cocaine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuroblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>